Great presentation.The question that no doubt everyone here...

Great presentation.
The question that no doubt everyone here would like the answered - " is management frustrated by the under performance of the share price".
When this question was put to BW he said that they were surprised that the s.p was so range bound given the progress the company is making and how the revenue guidance was increased. He offered basically two reasons, namely shares being sold as they came out of escrow, and the recent cash raise. He said there were a good number of upcoming catalysts that would give the s.p some momentum, namely a) increasing profit margins from around 73-75% now to over 80% within the next 3 years, b) acceleration of growth with the US market, c) strong product pipeline with large TAMs, d) more clinical data supporting their portfolio of products. Bottom line, I could see the facial reaction BW, JA & BM when they were asked the question and I could see that they were genuinely surprised with the current low s.p.
I haven't changed my view on the company and I feel assured that ARX will deliver the results to the shareholders.
Good luck.